Genetic Signatures Offer Clues about Prognosis in Castration-Resistance Prostate Cancer

October 14, 2012 by  
Filed under Prostate Cancer News

Two different studies carried out by researchers in the USA and England has revealed that gene signs could predict the survival chance of those affected by castration resistance prostate cancer.

The findings of the two separate studies were published in “The Lancelot Oncology”. The mortality rate for those with castration resistance prostate cancer is high and some treatments have been developed to extend the life of patients a few months.

With the identification of genetic biomarkers, it is more likely that better therapies could be developed. Here are more details on these new researches:

Two different genetic signatures may offer some clue about prognosis in castration-resistant prostate cancer.

In one study, a six-gene panel distinguished between patients with longer and shorter survival rates (P<0.0001), according to William Oh, MD, of Mount Sinai School of Medicine in New York, and colleagues.

In a second study, Johann de Bono, MD, of Royal Marsden NHS Foundation Trust in Surrey, England, and colleagues identified a set of nine genes that predicted poor survival (P<0.0001).

The studies were published online in The Lancet Oncology.

Castration-resistant prostate cancer typically carries a high mortality rate — though it is still highly variable — and treatments, including treatment with newer agents such as sipuleucel-T (Provenge), cabazitaxel (Jevtana), and abiraterone (Zytiga), usually extend life just a few months beyond expected survival.

Companies are still looking to develop treatments for this late-stage disease, but few genetic markers have been found that could serve as therapeutic targets.

Both groups of researchers conducted whole-blood gene profiling, looking for gene expression as measured for mRNA signatures.

Oh and colleagues used blood samples from 62 men with castration-resistant prostate cancer who were on various treatment regimens at Dana-Farber Cancer Institute in Boston to assess a panel of 168 inflammation-related and prostate cancer-related genes.

Ultimately, they derived a six-gene panel — ABL2, C1QA, SEMA4D, TIMP1, ITGAL, and CDKN1A — that separated patients in two groups: one low-risk group with a median survival of more than 34.9 months (the median survival actually was not reached in the trial) and a high-risk group with a median survival of 7.8 months (P<0.0001).

The panel’s prognostic utility was validated in an independent cohort of 138 patients from Memorial Sloan Kettering Cancer Center in New York, they reported.

The difference in survival was less prominent in this validation cohort (9.2 versus 18.5 months, HR 2.3, 95% CI 1.39 to 3.70), but it was associated with a significantly higher area under the curve compared with a clinico-pathological model (0.90 versus 0.65, P=0.0067).

The model “suggests possible dysregulation of the immune system,” they wrote. The protein products of ABL2, ITGAL, and SEMA4D are involved in T-cell motility, antigen surveillance, and T-helper-cell activity, while C1QA, CDKN1A, and TIMP1 are involved in macrophages and dendritic cells.

In the second study, de Bono and colleagues looked at mRNA expression in the blood of 64 patients with castration-resistant prostate cancer and compared it with that of 30 early prostate cancer patients who were slated for active surveillance, to come up with a nine-gene panel.

They found that patients in a certain genotype — latent process decomposition 1 (LPD1) — had features that were associated with poorer overall survival than those in other subgroups (LPD2, LPD3, and LPD4) (10.7 months versus 25.6 months, P<0.0001).

They confirmed the prognostic utility of the nine-gene panel in a validation cohort of 70 castrate-resistant prostate cancer patients and found that those in the LPD1 group had worse overall survival than the other three groups combined (9.2 months versus 21.6 months, P=0.001).

In an accompanying editorial, Karina Dalsgaard Sørensen, MD, of Aarhus University in Denmark, cautioned that the “biological relevance of these prognostic signatures, which are the first of their kind, is largely unknown.”

She noted that further investigation of the underlying biological mechanisms is needed, and future studies need to clarify whether “any of the 15 signature genes are functionally relevant, or are surrogate markers for other processes.”

“Whether these blood mRNA signatures will be true game changers for management of castration-resistant prostate cancer is too early to say,” she wrote. While their simplicity is attractive, she said, “large-scale prospective studies are needed to validate their biomarker potential.” Source.

Castration-resistance prostate cancer is that which can no longer yield to the effects of hormonal treatments.

Many treatments have been successfully manufactured and are potent in ensuring that men with this type of prostate cancer showing a high mortality risk are treated.

With the discovery of the gene biomarkers, better therapies are more likely to be manufactured to extend the lives of the patients.

It is advised that large-scale prospective studies be carried out fast to validate the potential of these genetic biomarkers.

Below Are Other Related Articles Among 1,000+ Prostate Cancer Articles On
This HUGE 4+ Year Old Prostate Cancer Victory Authority Website:

(95% of these 1,000+ Prostate Cancer Articles on this website
are written by our Expert In -house Writers, after lots of research.
The remaining 5% are news articles and videos from relevant sources!)


  1. Prostate Cancer Genetic “Signatures” That Help Predict Aggressiveness of Tumors Discovered by Researchers
  2. Management of Castration-Resistant Prostate Cancer
  3. Enzalutamide Improves Survival for Castration- Resistant Prostate Cancer in Phase III Clinical Trial
  4. MicroRNA 125b, a Molecule and new Target for Castration Resistant Prostate Cancer Identified
  5. US Oncologists to Prescribe Enzalutamide for Metastatic Castration-resistant Prostate cancer (mCRPC)
  6. Cabozantinib Shows More Efficacy in Treating Metastatic Castration-Resistant Prostate Cancer (CRPC)
  7. Prostate Cancer Md Phd Gene – Is Prostate Cancer Genetic?
  8. Is Prostate Cancer Genetic?
  9. Prostate Cancer and Melanoma Have Genetic Link with Parkinson’s Disease – Study
  10. Last Stage Of Prostate Cancer As above – The Prognosis Of The Disease

Speak Your Mind

Tell us what you're thinking... !

s